Abstract:Heterozygous mutations within the voltage-gated sodium channel α subunit ( SCN1A ) are responsible for the majority of cases of Dravet syndrome (DS), a severe developmental and epileptic encephalopathy. Development of novel therapeutic approaches is mandatory in order to directly target the molecular consequences of the genetic defect. The aim of the present study was to investigate whether cis-acting long non-coding RNAs (lncRNAs) of SCN1A are expressed in brain specimens of children and adolescent with epilepsy as these molecules comprise possible targets for precision-based therapy approaches. We investigated SCN1A mRNA expression and expression of two SCN1A related antisense RNAs in brain tissues in different age groups of pediatric non-Dravet patients who underwent surgery for drug resistant epilepsy. The effect of different antisense oligonucleotides (ASOs) directed against SCN1A specific antisense RNAs on SCN1A expression was tested. The SCN1A related antisense RNAs SCN1A -dsAS (downstream antisense, RefSeq identifier: NR_110598) and SCN1A -usAS (upstream AS, SCN1A -AS, RefSeq identifier: NR_110260) were widely expressed in the brain of pediatric patients. Expression patterns revealed a negative correlation of SCN1A-dsAS and a positive correlation of lncRNA SCN1A -usAS with SCN1A mRNA expression. Transfection of SK-N-AS cells with an ASO targeted against SCN1A -dsAS was associated with a significant enhancement of SCN1A mRNA expression and reduction in SCN1A -dsAS transcripts. These findings support the role of SCN1A -dsAS in the suppression of SCN1A mRNA generation. Considering the haploinsufficiency in genetic SCN1A related DS, SCN1A -dsAS is an interesting target candidate for the development of ASOs (AntagoNATs) based precision medicine therapeutic approaches aiming to enhance SCN1A expression in DS.

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to explore the expression of two antisense RNAs (antisense RNAs, asRNAs) related to the voltage - gated sodium channel α - subunit (SCN1A) gene, namely SCN1A downstream antisense RNA (SCN1A - dsAS) and SCN1A upstream antisense RNA (SCN1A - usAS), in the brain tissues of children and adolescents with epilepsy and their regulatory effects on SCN1A gene expression. Specifically, the study aims to: 1. **Evaluate the expression levels of SCN1A - related asRNAs**: Researchers detected the expression levels of SCN1A mRNA and two SCN1A - related asRNAs by analyzing surgical brain tissue samples from pediatric non - Dravet syndrome patients of different age groups. 2. **Explore the influence of asRNAs on SCN1A expression**: Researchers further explored how these asRNAs affect the expression of the SCN1A gene, especially whether SCN1A - dsAS has an inhibitory effect on the production of SCN1A mRNA, and whether SCN1A - usAS has a promoting effect. 3. **Verify the therapeutic potential of ASOs**: Researchers tested the effects of different antisense oligonucleotides (antisense oligonucleotides, ASOs) targeting SCN1A - dsAS on SCN1A expression to evaluate their potential as targets for the treatment of Dravet syndrome (DS). ### Research background Dravet syndrome (DS) is a severe developmental and epileptic encephalopathy, mainly caused by heterozygous loss - of - function mutations in the SCN1A gene. This mutation leads to haploinsufficiency of the Nav1.1 - type voltage - gated sodium channel, which in turn affects the synaptic Na+ current of fast - firing GABAergic inhibitory interneurons, resulting in impaired inhibitory function of downstream neurons. Currently, most DS patients are treated with multiple antiepileptic drugs, but few can fully control epileptic seizures, and cognitive, behavioral, and motor disorders usually cannot be effectively alleviated. Therefore, it is particularly important to develop treatment methods that directly target the molecular consequences of SCN1A gene defects. ### Research methods 1. **Patient selection**: Eighteen patients with refractory epilepsy who were ineffective to at least two commonly used antiepileptic drugs were selected from two tertiary epilepsy centers (Munich, Germany and Vogtland). 2. **Sample collection**: Three to four biopsy samples were collected from each patient, immediately frozen and stored, and RNA extraction was carried out. 3. **RNA extraction and quantitative RT - PCR**: Using TBP as an internal reference gene, the expression levels of SCN1A, SCN1A - dsAS, and SCN1A - usAS were detected by quantitative RT - PCR. 4. **ASO treatment**: Three ASOs targeting SCN1A - dsAS were designed and tested to evaluate their effects on SCN1A mRNA expression. ### Main results 1. **Expression levels**: SCN1A is the most abundantly expressed transcript, while the expression level of SCN1A - dsAS is the lowest, and the expression level of SCN1A - usAS is moderate. 2. **Correlation analysis**: The expression of SCN1A - dsAS is significantly negatively correlated with the expression of SCN1A mRNA (\( R^2 = 0.5 \), \( p < 0.0001 \)), while the expression of SCN1A - usAS is positively correlated with the expression of SCN1A mRNA (\( R^2 = 0.52 \), \( p < 0.0001 \)). 3. **ASO treatment effect**: ASO3 treatment significantly increased the expression of SCN1A mRNA (about 15 - fold, \( p < 0.001 \)), while reducing the expression of SCN1A - dsAS (about 40%, \( p < 0.05 \)). ### Discussion The research results support the role of SCN1A - dsAS in inhibiting the production of SCN1A mRNA, while SCN1A - usAS may have a promoting role. Given the haploinsufficiency of the SCN1A gene in DS patients, SCN1A - dsAS is an interesting target for the development of ASO - based precision medicine treatment strategies to enhance SCN1A expression in DS patients. This provides new ideas and directions for the future treatment of DS.

Brain expression profiles of two SCN1A antisense RNAs in children and adolescents with epilepsy